Embecta Corp.
embecta.comWhat Do They Do?
Sells pen needles, insulin syringes and safety injection devices for people living with diabetes and healthcare providers.
10-K for FY2025, filed Nov 25, 2025
How Do They Make Money?
Embecta sells diabetes devices mainly to wholesalers and distributors; customers generally pay within a year after products ship or are delivered.
10-K for FY2025, filed Nov 25, 2025The Company recognizes revenue from product sales and considers performance obligations satisfied when the customer obtains control of the…View ↗
The Company’s policies for recognizing revenue have not changed from those described in the Company's Annual Report on Form 10-K for the…View ↗
Payment terms extended to the Company’s customers are based upon commercially reasonable terms for the markets in which the Company’s…View ↗
-
10-K for FY2025, filed Nov 25, 2025
FY2025 revenue by product or service ↗
$1.1B
-
10-K for FY2025, filed Nov 25, 2025
$1.1B ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Pen Needles
Sold outright
10-K for FY2025, filed Nov 25, 2025 |
73%
FY2022: 73%
|
Pen Needles, FY2025
$784.1M Sources
|
Sold outright |
|
Syringes
Sold outright
10-K for FY2025, filed Nov 25, 2025 |
12%
FY2022: 14%
|
Syringes, FY2025
$124.6M Sources
|
Sold outright |
|
Safety
Sold outright
10-K for FY2025, filed Nov 25, 2025 |
13%
FY2022: 11%
|
Safety, FY2025
$137.8M Sources
|
Sold outright |
|
Other
Sold outright
|
1.3%
FY2022: 1.3%
|
Other, FY2025
$14M Sources
|
Sold outright |
|
Contract Manufacturing
|
1.8%
FY2022: 1.3%
|
Contract Manufacturing, FY2025
$19.9M Sources
|
Who Are Their Customers?
Embecta mainly sells through wholesalers and distributors, which supply retail and institutional channels. In some markets, its sales teams call on payers, retailers, wholesalers, healthcare providers and pharmacies.
10-K for FY2025, filed Nov 25, 2025
Do Revenues Turn Into Profits?
Yes. It kept 9 cents of every revenue dollar as net income in FY2025 and turned 17 cents into free cash flow.
10-K for FY2025, filed Nov 25, 2025
$242.1MView ↗
10-K for FY2025, filed Nov 25, 2025
$95.4MView ↗
10-K for FY2025, filed Nov 25, 2025
$182.4MView ↗
How Are They Changing?
10-Q for Q3 FY2026, filed Aug 7, 2026
Open tableView ↗
-
Aug 7, 2026
Raised adjusted operating margin and earnings guidance
Embecta reaffirmed its revenue range and raised full-year ranges for adjusted operating margin and adjusted earnings per share.
Sources
8-K, filed Aug 7, 2026
Mr. Kurdikar concluded, "Given our year-to-date performance, we are reaffirming our fiscal year revenue guidance range and raising our full…View ↗
-
May 15, 2026
Completed acquisition of Owen Mumford
The acquisition adds drug-delivery technologies and chronic-care devices alongside Owen Mumford's medical-device business.
Sources
8-K, filed May 15, 2026
On May 15, 2026, Embecta Corp. (“embecta”) completed its previously announced acquisition (the “Transaction”) of all of the issued share…View ↗
-
Mar 20, 2026
Agreed to acquire Owen Mumford
The deal includes an upfront payment and additional payments tied to commercial milestones for the Aidaptus auto-injector platform.
Sources
8-K, filed Mar 20, 2026
On March 19, 2026, Embecta Corp. (“embecta”) entered into a definitive Agreement for the Sale and Purchase of Owen Mumford Holdings Limited…View ↗
Flat. Revenue was $1.1B in FY2025, about the same as the $1.2B of FY2021.
Stopped patch pump development
The older report described an insulin patch pump in development; the latest says Embecta ended investment in the program and discontinued its commercial plans for an insulin delivery system.
10-K for FY2022, filed Dec 22, 2022 10-K for FY2025, filed Nov 25, 2025For example, we are currently working on developing an insulin patch pump focused on serving the needs of people living with Type 2…View ↗
On November 22, 2024, the Company's Board of Directors approved a plan to discontinue internal and external investment in the research and…View ↗
Broader development focus
The older report described an insulin patch pump in development, while the latest also explores products outside diabetes, including drug delivery and chronic care.
10-K for FY2022, filed Dec 22, 2022 10-K for FY2025, filed Nov 25, 2025For example, we are currently working on developing an insulin patch pump focused on serving the needs of people living with Type 2…View ↗
We are also exploring the development of products that allow us to expand our portfolio outside of diabetes. For example, we intend to work…View ↗
Who Do They Compete With?
Competes with Novo Nordisk, MTD Group, and Terumo Medical
10-K for FY2025, filed Nov 25, 2025Companies with whom we currently compete in the diabetes drug injection business include Novo Nordisk, MTD Group, and Terumo Medical…View ↗
Loading...
